Integra Lifesciences (IART) reported $1.6B in revenue for fiscal 2025, +1.5% year on year. That ranks #1460 by revenue among 2853 SEC filers and #131 in Healthcare. It posted a net loss of −$517M for the same year. Revenue has grown 5.7% a year on average since 2016 ($992M then). The fiscal 2025 balance sheet shows $3.6B in total assets, $235M in cash and $727M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.6B | +1.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $851M | −10.7% | FY20202020-12-31 |
| Operating incomeOperatingIncomeLoss | −$493M | −$522M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$517M | −$510M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $50.4M | −61.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $81.4M | −22.0% | FY20252025-12-31 |
| Total assetsAssets | $3.6B | −10.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.0B | −32.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $235M | −4.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $727M | −4.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $392M | −$4.6M | Open → |
| Q2 20262026-06-30 | $419M | $4.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 152 of 161 companies compared | −31.6% | |
| Operating marginRank 153 of 160 companies compared | −30.2% | |
| R&D as share of revenueRank 67 of 102 companies compared | 6.1% | |
| Cash as share of revenueRank 69 of 160 companies compared | 14.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Integra Lifesciences Holdings Corp
- Ticker
- IART
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0000917520
Filings
- 10-QJul 29, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Healthcare ServicesHCSG | $1.8B | $59.1M |
| 111YI | $1.8B | −$3.2M |
| PTC TherapeuticsPTCT | $1.7B | $683M |
| Integra LifesciencesIART | $1.6B | −$517M |
| Lantheus HoldingsLNTH | $1.5B | $234M |
| National HealthcareNHC | $1.5B | $120M |
| Merit Medical SystemsMMSI | $1.5B | $128M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Integra Lifesciences — Key figures |url=https://companiesranked.com/en/company/integra-lifesciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Integra Lifesciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/integra-lifesciencesBibTeX
@misc{companiesranked-en-company-integra-lifesciences-2026,
author = {{CompaniesRanked}},
title = {{Integra Lifesciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/integra-lifesciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000917520-26-000011 · February 26, 2026
{{cite web |title=Integra Lifesciences — Key figures — 10-K (0000917520-26-000011) |url=https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/iart-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.